Impact of Cardio-Selective Beta-Blockers on Infarct Size After Acute Myocardial Infarction

Recruiting now

Conditions studied: STEMI

In brief

Introduction: The effect of intravenous beta-blockers on the extent of the necrotic area, after primary percutaneous transluminal coronary angioplasty (PTCA), for acute myocardial infarction is not well established. Purpose: The present study aims to investigate, whether the early intravenous administration of landiolol, a highly cardioselective b-blocker, reduces the extent of the necrotic area after ST-elevation myocardial infarction (STEMI). Methods: This prospective observational cohort study will enroll patients presenting with STEMI, who undergo primary PCI and receive either intravenous landiolol or standard oral β-blocker therapy, in accordance with current European Society of Cardiology (ESC) guidelines. Eligibility will be determined by predefined inclusion and exclusion criteria. Treatment selection will be based solely on the clinical judgment of the attending cardiologist, without randomization. Results: Final infarct size will be quantified by cardiac magnetic resonance imaging (CMR) performed at least three months after the STEMI to minimize edema-related overestimation. Myocardial function will be assessed during hospitalization using transthoracic echocardiography, including measurement of global longitudinal strain (GLS). Additional data will include serial high-sensitivity troponin and creatine phosphokinase (CPK) measurements, 24-hour continuous electrocardiographic monitoring for arrhythmia burden, and predefined safety outcomes collected throughout hospitalization.

Key facts

Study ID: NCT07293832
Run by: Aristotle University Of Thessaloniki
People needed: 100
Starts: 2024-11-13
Expected to finish: 2026-08-01
Last updated by the study team: 2025-12-19

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Age between 18 and 80 years
Patients with electrocardiogram showing ST-segment elevation ≥2 mm in 2 or more contiguous leads for more than 30 minutes
Estimated time from symptom onset to reperfusion ≤12 hours
Patients scheduled to undergo primary angioplasty
Patients who have signed a consent form

You may not qualify if…

Patients receiving chronic medication with beta-adrenergic blockers
Patients with a previous myocardial infarction
Persistent systolic blood pressure <90 mmHg
Persistent heart rate <55 beats per minute
Patients with Killip class III (acute pulmonary edema) or IV (cardiogenic shock) on initial examination
12-lead electrocardiogram with PR interval >200 milliseconds
12-lead electrocardiogram showing second- or third-degree atrioventricular block
Bronchospasm requiring bronchodilator treatment
Possible pregnancy or postpartum period
Inability or refusal to sign the consent form

Where it is running

Hippokration General Hospital of Thessaloniki — Thessaloniki, Thessaloniki, Greece (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.